
|Videos|April 20, 2022
Clinical Phenotypes in Patients with Myelofibrosis
Author(s)John Mascarenhas, MD
Dr John Mascarenhas explains the differences between myelofibrosis phenotypes and why it affects treatment regimen choices.
Advertisement
Case: A 76-Year-Old Woman with Myelofibrosis
Initial presentation
- SM is a 76 y/o woman who visits her primary care physician for her annual checkup. She reports having fatigue, occasional night sweats and abdominal discomfort under left rib for the past 2 months. She also mentioned that she feels pain in her bones, but she just attributes that to her “old age.”
- SM spends most of her days gardening followed by baking, her 2 favorite activities. Lately, she feels tired after just spending 1 hour gardening and has no energy to bake afterwards.
- Since her last examination a year ago, SM has lost close to 12 lbs. She says she has not been dieting and has not noticed a change in her eating habits.
- PMH:
- Hypertension (controlled)
- Glaucoma
- Asthma (controlled with inhalers)
- SMH: (-) nonsmoker; has an occasional drink during book club with her girlfriend
- FH: she lives alone but her daughter and sister live close by; no family history of cancer
- PE: abdominal exam reveals spleen palpable 4cm below left coastal margin visible bruising
Clinical workup
- Current Labs: (baseline labs were within normal limits at her last examination one year ago)
- Platelet count: 44 x 109/L
- Hgb: 8g/dL
- WBC count: 27 x 109/L
- Bone Marrow Biopsy
- Shows a hypercellular bone marrow, increase in atypical appearing megakaryocytes and MF-2 fibrosis, no increase in blasts by CD34+ IHC, aspirate without spicules
- Molecular testing
- JAK-V617F mutation: positive at 44%, NGS panel only identified TET2 mutation at a VAF of 17%
- JAK-V617F mutation: positive at 44%, NGS panel only identified TET2 mutation at a VAF of 17%
Treatment
- SM complaining of increasing fatigue and abdominal pain and on PE, shows splenomegaly
- Treatment started with pacritinib 200mg BID
Advertisement
Related to this article

Five-year OLYMPUS data show Jelmyto (UGN-101) sustains kidney-sparing control in low-grade UTUC, with most responders remaining event-free.

New study shows CT-measured body fat, not BMI, links obesity to higher lung cancer risk via immune T-cell changes—hinting at prevention through weight loss.

The IMpactMF trial was discontinued after an independent committee determined imetelstat was unlikely to improve overall survival.

The EGFR x LGR5 bispecific antibody petosemtamab demonstrated improved overall survival and overall response rate when added to pembrolizumab in head and neck squamous cell carcinoma.

COA urges Supreme Court review of Mississippi 340B contract pharmacy law, spotlighting PBM influence, drug access concerns, and calls for tighter oversight.

LITESPARK-012 data at ESMO 2026 show that adding belzutifan or quavonlimab to pembrolizumab/lenvatinib did not improve survival for advanced kidney cancer.
Advertisement
Advertisement
Trending on Targeted Onc
1
ESMO 2026: ADCs and New Combinations Advance Lung Cancer Care
2
Novel ADCs Show Responses in Ovarian and Cervical Cancer at ESMO 2026
3
ESMO 2026: New Data Advance Prostate, Kidney, and Bladder Cancer Care
4
340B Contract Pharmacy Case Rekindles Scrutiny Over Program Intent
5

